| scholarly article | Q13442814 |
| P2093 | author name string | Brian I Carr | |
| P2860 | cites work | Hepatocellular carcinoma: pilot trial of treatment with Y-90 microspheres | Q41761671 |
| P433 | issue | 2 Suppl 1 | |
| P921 | main subject | hepatocellular carcinoma | Q1148337 |
| microsphere | Q1759020 | ||
| P304 | page(s) | S107-10 | |
| P577 | publication date | 2004-02-01 | |
| P1433 | published in | Liver Transplantation | Q15730498 |
| P1476 | title | Hepatic arterial 90Yttrium glass microspheres (Therasphere) for unresectable hepatocellular carcinoma: interim safety and survival data on 65 patients | |
| P478 | volume | 10 |
| Q41881660 | (210)Po microsphere radiological design for tumor vascular disruption |
| Q38465831 | (90)Y-glass microspheres for hepatic neoplasia |
| Q38162894 | 90Y radioembolization versus chemoembolization in the treatment of hepatocellular carcinoma: an analysis of comparative effectiveness |
| Q37122717 | Advances in experimental and translational research in the treatment of hepatocellular carcinoma |
| Q41584458 | Combined sorafenib and yttrium-90 radioembolization for the treatment of advanced hepatocellular carcinoma. |
| Q38936579 | Comparison of the Adverse Event Profile of TheraSphere® with SIR-Spheres® for the Treatment of Unresectable Hepatocellular Carcinoma: A Systematic Review |
| Q47573274 | Comparison of transcatheter arterial chemoembolization and microsphere embolization for treatment of unresectable hepatocellular carcinoma: a meta-analysis |
| Q57160338 | Conversion therapy and suitable timing for subsequent salvage surgery for initially unresectable hepatocellular carcinoma: What is new? |
| Q87604943 | Current management of hepatocellular carcinoma |
| Q26744307 | Current status of transarterial radioembolization |
| Q33830713 | Direct in vivo injection of 131I-GMS and its distribution and excretion in rabbit |
| Q61827005 | EANM procedure guideline for the treatment of liver cancer and liver metastases with intra-arterial radioactive compounds |
| Q36673829 | Efficacy and safety of transarterial radioembolization versus chemoembolization in patients with hepatocellular carcinoma. |
| Q37353089 | Evidence-based diagnosis and locoregional therapy for hepatocellular carcinoma |
| Q36656612 | Factors associated with increased incidence of severe toxicities following yttrium-90 resin microspheres in the treatment of hepatic malignancies |
| Q40072454 | Hepatic artery and biliary complications in liver transplant recipients with radioembolization bridging treatment for hepatocellular carcinoma. |
| Q42015157 | Hepatic intra-arterial infusion of yttrium-90 microspheres in the treatment of recurrent hepatocellular carcinoma after liver transplantation: a case report. |
| Q38704940 | Hepatic radioembolization complicated by gastrointestinal ulceration. |
| Q81544297 | Hepatocellular carcinoma: current treatment strategies |
| Q38984450 | In intermediate stage hepatocellular carcinoma: radioembolization with yttrium 90 or chemoembolization? |
| Q44546861 | Intrahepatic flow redistribution in patients treated with radioembolization |
| Q47925759 | Liver disease induced by radioembolization of liver tumors: description and possible risk factors |
| Q36943316 | Liver embolizations in oncology. A review. Part II. Arterial radioembolizations, portal venous embolizations, experimental arterial embolization procedures |
| Q37625817 | Liver transplantation after radioembolization in a patient with unresectable HCC. |
| Q36563672 | Liver-directed therapies for patients with primary liver cancer and hepatic metastases |
| Q39241689 | Long-Term Outcome After Liver Transplantation for Hepatocellular Carcinoma Following Yttrium-90 Radioembolization Bridging Treatment. |
| Q36865115 | Long-term follow-up study of gastroduodenal lesions after radioembolization of hepatic tumors |
| Q29616230 | Management of hepatocellular carcinoma |
| Q30252143 | Management strategies for hepatocellular carcinoma: old certainties and new realities. |
| Q51097558 | Mid-term results in otherwise treatment refractory primary or secondary liver confined tumours treated with selective internal radiation therapy (SIRT) using (90)Yttrium resin-microspheres. |
| Q30468280 | Minimally invasive image-guided therapy for inoperable hepatocellular carcinoma: What is the evidence today? |
| Q37578521 | Nonsurgical treatment for localized hepatocellular carcinoma. |
| Q34478383 | Outcome of 1000 liver cancer patients evaluated at the UPMC Liver Cancer Center |
| Q36194191 | PET/CT-Based Dosimetry in 90Y-Microsphere Selective Internal Radiation Therapy: Single Cohort Comparison With Pretreatment Planning on (99m)Tc-MAA Imaging and Correlation With Treatment Efficacy |
| Q36874720 | PET/MRI of Hepatic 90Y Microsphere Deposition Determines Individual Tumor Response |
| Q34618735 | Predictors of repeat transarterial chemoembolization in the treatment of hepatocellular carcinoma |
| Q35658025 | Predictors of response to radio-embolization (TheraSphere®) treatment of neuroendocrine liver metastasis. |
| Q50975763 | Preparation of doxorubicin-containing chitosan microspheres for transcatheter arterial chemoembolization of hepatocellular carcinoma. |
| Q35535968 | Presentation and outcomes of hepatocellular carcinoma patients at a western centre |
| Q35094057 | Prophylactic Embolization of the Cystic Artery Before Radioembolization: Feasibility, Safety, and Outcomes |
| Q57433607 | Radiation Therapy for Hepatocellular Carcinoma |
| Q37113543 | Radioembolization for the treatment of unresectable hepatocellular carcinoma: a clinical review |
| Q33820777 | Radioembolization of hepatic tumors |
| Q34563515 | Radioembolization of yttrium-90 microspheres for hepatic malignancy |
| Q27023616 | Radioembolization with Yttrium-90 microspheres in hepatocellular carcinoma: Role and perspectives |
| Q36728823 | Radioembolization with Yttrium-90 microspheres: review of an emerging treatment for liver tumors |
| Q35721324 | Radioembolization with yttrium-90 resin microspheres for neuroendocrine tumor liver metastases |
| Q37972813 | Radiotherapeutic strategies in the management of hepatocellular carcinoma |
| Q38191225 | Regional hepatic therapies: an important component in the management of colorectal cancer liver metastases |
| Q25257869 | Relationship of 99mtechnetium labelled macroaggregated albumin (99mTc-MAA) uptake by colorectal liver metastases to response following Selective Internal Radiation Therapy (SIRT) |
| Q35111887 | Research reporting standards for radioembolization of hepatic malignancies. |
| Q64235937 | Review of therapies for intermediate and advanced stage hepatocellular carcinoma, not suitable for curative therapies: a rapidly changing landscape |
| Q34585175 | Safety and efficacy of 90Y radiotherapy for hepatocellular carcinoma with and without portal vein thrombosis |
| Q28071594 | Selective Internal Radiation Therapy (SIRT) as Conversion Therapy for Unresectable Primary Liver Malignancies |
| Q39491049 | Selective internal radiation therapy for gastrointestinal neuroendocrine tumour liver metastases: a new and effective modality for treatment |
| Q44441242 | Selective internal radiation therapy with 90Y microspheres for colorectal liver metastases: single-centre experience with 100 patients |
| Q26821887 | Side effects of yttrium-90 radioembolization |
| Q33410714 | Splenomegaly-associated thrombocytopenia after hepatic yttrium-90 radioembolization |
| Q51259014 | Successful embolization of hepatocelluar carcinoma with yttrium-90 glass microspheres prior to liver transplantation. |
| Q50535030 | Survival after yttrium-90 resin microsphere radioembolization of hepatocellular carcinoma across Barcelona clinic liver cancer stages: a European evaluation. |
| Q36060731 | The effects of hepatic artery chemotherapy on viral hepatitis in patients with hepatocellular carcinoma. |
| Q35931183 | The optimal selection of radiotherapy treatment for hepatocellular carcinoma |
| Q26996805 | The role of interventional radiology in the management of hepatocellular carcinoma |
| Q33691454 | Therapeutic equivalence in survival for hepatic arterial chemoembolization and yttrium 90 microsphere treatments in unresectable hepatocellular carcinoma: a two-cohort study |
| Q34991390 | Trans-arterial hepatic radioembolisation of yttrium-90 microspheres |
| Q26753089 | Transarterial Radioembolization with Yttrium-90 for the Treatment of Hepatocellular Carcinoma |
| Q26852174 | Transarterial radioembolization using yttrium-90 microspheres in the treatment of hepatocellular carcinoma: a review on clinical utility and developments |
| Q34628257 | Transarterial therapies for hepatocellular carcinoma. |
| Q36201164 | Treatment of hepatocellular carcinoma by means of radiopharmaceuticals |
| Q42287138 | Treatment of neuroendocrine tumor liver metastases |
| Q38619331 | Tumor vascular disruption using various radiation types |
| Q38022739 | Update on yttrium-90-based radio-embolization for treatment of hepatocellular carcinoma |
| Q46132216 | Use of yttrium-90 microsphere radioembolization of hepatocellular carcinoma as downstaging and bridge before liver transplantation: a case report. |
| Q35888586 | Usefulness and pitfalls of MAA SPECT/CT in identifying digestive extrahepatic uptake when planning liver radioembolization. |
| Q37689792 | YCl3 Promotes Neuronal Cell Death by Inducing Apoptotic Pathways in Rats |
| Q26743603 | Yttrium-90 Selective Internal Radiation Therapy with Glass Microspheres for Hepatocellular Carcinoma: Current and Updated Literature Review |
| Q34874473 | Yttrium-90 microsphere radioembolization for the treatment of liver malignancies: a structured meta-analysis |
| Q38083431 | Yttrium-90 radioembolization for hepatocellular carcinoma: what we know and what we need to know |
| Q34563356 | Yttrium-90 radioembolization of hepatocellular carcinoma and metastatic disease to the liver |
| Q53061048 | [Selective internal radioembolization in nonresectable hepatocellular carcinoma]. |
Search more.